Focus: Santen is a specialty biotechnology company focused exclusively on ophthalmology, headquartered in Emeryville, CA with a recently established US presence. The company operates a portfolio of marketed eye-care products alongside a robust pipeline targeting glaucoma, dry eye, presbyopia, and retinal diseases.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Cooling — net -6 jobs in 30d
23 added, 29 removed. Slower than typical.
Santen offers specialized ophthalmology depth and pipeline momentum but carries execution risk due to patent cliffs and nascent US operations; best suited for candidates prioritizing therapeutic focus over financial visibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Established ophthalmic product facing near-term generic competition, likely in allergy or inflammation category.
Help build intelligence for Santen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Santen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA-approved ophthalmic agent approaching loss of exclusivity with no disclosed transition strategy.
Third marketed product in near-term LOE category, completing a portfolio at inflection point.
Santen Pharmaceutical Lifts Earnings and Dividends, Signals Growth for FY2027 - TipRanks
Santen Pharmaceutical Lifts Earnings and Dividends, Signals Growth for FY2027 TipRanks
Santen Pharmaceutical stock (JP3512800005): Japanese eye?care specialist eyes growth in global marke - AD HOC NEWS
Santen Pharmaceutical stock (JP3512800005): Japanese eye?care specialist eyes growth in global marke AD HOC NEWS
Santen bags China rights to 5 glaucoma drugs from AbbVie - BioSpectrum Asia
Santen bags China rights to 5 glaucoma drugs from AbbVie BioSpectrum Asia
Santen Pharmaceutical Korea Appoints Jinhee Kim as New CEO - 아시아경제
Santen Pharmaceutical Korea Appoints Jinhee Kim as New CEO 아시아경제
Santen sharpens China focus under global development strategy - China Daily
Santen sharpens China focus under global development strategy China Daily
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo